FDA Plans Behind-The-Counter Drugs Meeting, Mulls “Transitional” Status
This article was originally published in The Tan Sheet
FDA will discuss the idea of behind-the-counter drug sales as a possible transitional stage between Rx and OTC status when it holds a forum on the topic with stakeholders
You may also be interested in...
The Government Accountability Office's anticipated updated report on a behind-the-counter class of drugs will help shape FDA's policy, according to Connie T. Jung, senior policy advisor for Pharmacy Affairs
FDA's Drug Safety and Risk Management Advisory Committee will be a tougher venue for drug sponsors during the next four years - long-time consumer advocate Sidney Wolfe recently was named a permanent committee member
There is one thing agreed on by opponents and proponents of assigning drugs to behind-the-counter status, including representatives from the pharmaceutical industry, drug retailers, the pharmacy and medical professions, researchers and consumer advocates: FDA will need a long time to reach a decision on the issue, they say